1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Touchstone International Medical Science Co. Ltd. Class A

Touchstone International Medical Science Co. Ltd. Class A

SSSE:688013
21.47
CNY
+0.10
(+0.47%)
0.77EPS
31.96P/E
2.00BMarket Cap
Touchstone International Medical Science Co. Ltd. Class A
SSE:688013
(Shanghai Stock Exchange)

Recent

price

21.47

P/E

ratio

31.96

div

yld

8.52%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.48
2.01
2.88
2.52
2.68
2.9
3.22
3.41
4.07
3.57
Revenue per Share
0.23
0.39
0.7
0.54
0.52
0.54
0.6
0.65
1.06
0.77
Basic EPS, GAAP
-0.12
0.23
0.42
0.54
0.65
0.03
0.82
0.14
-0.23
- -
Free Cash Flow per Basic Share
- -
0.3
0.35
- -
0.2
0.2
0.25
0.48
1.51
1.83
Dividend per Share
1.33
1.38
1.79
5.82
6.4
6.26
7.04
7.16
6.97
6.1
Book Value per Share
1.27
1.32
1.73
5.78
6.36
5.75
6.55
6.67
6.46
5.61
Tangible Book Value per Share
60
59
60
65
80
80
79
80
80
80
Basic Weighted Avg Shares
90
119
173
163
214
232
254
272
327
287
Sales/Revenue/Turnover
14.03
18.77
25.44
18.31
13.62
14.73
12.83
17.79
23.15
17.11
Operating Margin (%)
1
4
6
7
7
8
10
11
13
- -
Depreciation Expense
14
23
42
35
41
43
47
52
85
62
Net Income, GAAP
17.59
14.85
13.56
13.07
10.14
6.27
1.33
5.36
10.49
9.08
Effective Tax Rate (%)
15.51
19.43
24.32
21.4
19.38
18.62
18.65
19.05
26.07
21.64
Profit Margin (%)
25
11
33
392
435
375
424
394
289
197
Working Capital
- -
- -
- -
- -
- -
1
1
1
15
33
LT Debt
80
83
107
466
512
508
572
581
566
495
Total Equity
- -
23.11
38.59
10.37
8.19
8.02
8.39
8.97
14.29
10.35
Return on Invested Capital (%)
- -
27.36
42.54
12.2
8.48
8.49
8.75
9.01
14.27
10.38
Return on Capital (%)
- -
28.43
44.2
12.2
8.47
8.47
8.76
9
14.85
11.63
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
35
66
98
LT Borrowings
14
9
32
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
81
81
81
Market Capitalization
3,902
3,017
2,002

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
377
368
329
Cash, Cash Equivalents & STI
294
286
252
Accounts Receivable, Net
42
32
24
Inventories
34
41
38
Total Current Liabilities
88
104
131
Payables & Accruals
- -
- -
- -
ST Debt
35
66
98
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.12%
-2.73%
Free Cash Flow
- -
374.27%
-263.61%
Net Income, GAAP
- -
21.24%
64.15%
Sales/Revenue/Turnover
- -
15.21%
19.96%
Total Cash Common Dividend
- -
- -
217.39%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
60
73
69
70
272
2025
66
90
- -
83
327
2026
56
58
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.22
0.18
0.11
0.65
2025
0.17
0.44
- -
0.16
1.06
2026
0.12
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.48
0.48
2025
0.51
0.52
- -
0.5
1.51
2026
0.01
0.8
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Touchstone International Medical Science Co., Ltd. (688013.SS) researches, develops, manufactures and sells advanced surgical staplers and related medical devices for use in laparoscopic and open surgeries across thoracic, gastrointestinal, hepatobiliary, splenic and pancreatic, general and urology procedures. The company's core products encompass intraluminal staplers; endoscopic linear cutters and reloads; linear cutters and reloads; auto purse string clamps; linear staplers and reloads; as well as proctological, circumcision and circular staplers. Touchstone operates primarily in China with international sales in the United States, Europe, Japan, Russia, Brazil, Canada, Australia and other markets including Italy, Spain, Austria, South Korea and the United Kingdom. Founded in 2003 and headquartered in Suzhou, Jiangsu Province, China, the company maintains complete control over its supply chain and quality processes, with products approved by regulators such as the FDA, CE Mark, TGA and others. In recent developments, Touchstone advances its integrated intelligent surgical platform and end-effector project, with production line process validation completed and technical performance verification underway as of November 2025; the company also completed a share repurchase program totaling 3.09% of its shares by April 2025 and reported no repurchases in August 2025.